Draft Genome Sequence of an Extensively Drug-Resistant
Mycobacterium tuberculosis
Clinical Isolate of the Ural Strain

Shamsudheen Karuthedath Vellarikkal,a Ajay Vir Singh,c Pravin Kumar Singh,c Parul Garg,c Viswa Mohan Katoch,c Kiran Katoch,c
Open Source Drug Discovery Consortium,d D. S. Chauhan,c Vinod Scaria,b Sridhar Sivasubbua

Genomics and Molecular Medicine, CSIR Institute of Genomics and Integrative Biology, Delhi, Indiaa; GN Ramachandran Knowledge Center for Genome Informatics, CSIR Institute of Genomics and Integrative Biology, Delhi, Indiab; National JALMA Institute of Leprosy and Other Mycobacterial Diseases, Tajganj, Agra, Indiac; CSIR Open Source Drug Discovery Unit, Anusandhan Bhavan, New Delhi, Indiad We describe the genome sequencing and analysis of a clinical isolate of Mycobacterium tuberculosis belonging to the Ural strain
OSDD493 from India.

Received 2 October 2013 Accepted 4 October 2013 Published 7 November 2013
Citation Karuthedath Vellarikkal S, Vir Singh A, Kumar Singh P, Garg P, Mohan Katoch V, Katoch K, Open Source Drug Discovery Consortium, Chauhan DS, Scaria V, Sivasubbu S.
2013. Draft genome sequence of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate of the Ural strain OSDD493. Genome Announc. 1(6):e00928-13. doi:
Copyright 2013 Karuthedath Vellarikkal et al. This is an open-access article distributed under the terms of
Address correspondence to Sridhar Sivasubbu, [email protected], or Vinod Scaria, [email protected].
Tuberculosis is caused by a closely related group of pathogenic CLCGenomicsWorkbench6.Theassemblyresultedin193contigsat
organisms known as the Mycobacterium tuberculosis complex.
N50 values of 42,650 bp and a total assembly of 4,227,747 bp. Further, Distinct lineages of Mycobacterium tuberculosis have been reported automated gene prediction on the draft genomes was performed us- and have been characterized and classified based on spoligotype pat- ing the RAST server Analysis revealed 4,223 genes, including 42 terns. The six major distinct lineages are the Indo-Oceanic (EAI), East Asian (Beijing), East African-Indian (CAS), Euro-American (Haar- Nucleotide sequence accession numbers. This whole-genome
lem, LAM, T, X), West African I (AFRI1), and West African lineage II shotgun project has been deposited at DDBJ/EMBL/GenBank un- (AFRI2) lineages The Ural spoligotype was initially identified der the accession number The version described from the Ural region in Russia, which has one of the highest inci- in this paper is version AVQJ01000000.
dences of tuberculosis in the country. Nevertheless, the Ural spoligo-type forms a minority of genotypes of M. tuberculosis strains isolated ACKNOWLEDGMENTS
from this region The genotype has also been reported from across We thank Swati Subodh (TCGA) and Nupur Mehrotra (Premas Biotech) Eurasia and Central Asia and forms a significant proportion of geno- for scientific discussions and help in maintaining the strains. We also types observed in some of these regions. The Ural genotype is thought acknowledge S. Ramachandran for valuable input.
to be associated with significantly low transmissibility, pathogenicity, The project was funded by CSIR India through the Open Source Drug Discovery Programme (HCP001). The sequencing facility is supported Understanding the genome sequence of the Ural strain of Myco- through grants SIP006 and FAC002 from CSIR, India, and the computa- bacterium tuberculosis would provide immense insights into the tional analysis was performed at the CSIR Center for In Silico Biology at genomic architecture associated with low pathogenicity. In this pa- per, we describe the draft genome sequence of an extensively drug-resistant clinical isolate of Mycobacterium tuberculosis conforming to REFERENCES
a novel spoligotype clustering within the Ural spoligotype. The clini- 1. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA,
Allix C, Aristimuño L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi
cal isolate OSDD493 was obtained from the strain repository main- A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Fer-
tained at the National JALMA Institute of Leprosy and other Myco- dinand S, Garcia de Viedma D, Garzelli C, Gazzola L, Gomes HM,
bacterial Diseases, which is part of the Open Source Drug Discovery Guttierez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN,
Open Access Repository. Spoligotyping was performed and drug sen- Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ho ML, Martin
sitivity was evaluated per standard protocols Drug sensitivity C, Martin C, Mokrousov I, Narvskaïa O, Ngeow YF, Naumann L,
Niemann S, Parwati I, Rahim Z, Rasolofo-Razanamparany V, Ra-

analysis revealed the isolate to be resistant to streptomycin, rifampin, solonavalona T, Rossetti ML, Rüsch-Gerdes S, Sajduda A, Samper S,
isoniazid, ethambutol, ofloxacin, kanamycin, and ethionamide and Shemyakin IG, Singh UB, Somoskovi A, Skuce RA, van Soolingen D,
sensitive to amikacin, pyrazinamide, capreomycin, cycloserine, and Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC,
para-aminosalicylate sodium (PAS). DNA was isolated per standard Warren RM, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. 2006.
Mycobacterium tuberculosis complex genetic diversity: mining the fourth
protocols. The raw sequence data were generated after library prepa- international spoligotyping database (SpolDB4) for classification, popula- ration on Ion Torrent PGM according to protocols recommended by tion genetics and epidemiology. BMC Microbiol. 6:23.
the manufacturers. Draft genomes were assembled de novo using 2. Kovalev SY, Kamaev EY, Kravchenko MA, Kurepina NE, Skorniakov SN.
November/December 2013 Volume 1 Issue 6 e00928-13 2005. Genetic analysis of Mycobacterium tuberculosis strains isolated in Ural 6. National Committee for Clinical Laboratory Standards. 2002. Suscepti-
region, Russian Federation, by MIRU-VNTR genotyping. Int. J. Tuberc.
bility testing of mycobacteria, Nocardia, and other aerobic actinomycetes.
Lung Dis. 9:746 –752.
Tentative standard M24T2, 2nd ed. National Committee for Clinical Lab- 3. Mokrousov I. 2012. The quiet and controversial: Ural family of Mycobac-
terium tuberculosis. Infect. Genet. Evol. 12:619 – 629.
7. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA,
4. Mokrousov I, Vyazovaya A, Otten T, Zhuravlev V, Pavlova E, Tarash-
Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial
kevich L, Krishevich V, Vishnevsky B, Narvskaya O. 2012. Mycobacterium
drug sensitivity, and the use of sensitivity tests in tuberculosis control pro- tuberculosis population in northwestern Russia: an update from Russian- grammes. Bull. World Health Organ. 41:21– 43.
EU/Latvian border region. PLoS One 7:e41318.
8. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma
5. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D,
K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman
Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van
AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch
Embden J. 1997. Simultaneous detection and strain differentiation of
GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O.
Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Mi- 2008. The RAST server: rapid annotations using subsystems technology.
crobiol. 35:907–914.
BMC Genomics 9:1471–2164.
November/December 2013 Volume 1 Issue 6 e00928-13


Short report Homeopathy service in a National Health Service community menopause clinic: audit of clinical outcomes School of Health and Related Research, University of Sheffield, Sheffield, UKsubstances. These doses (usually in tablet form) are Sheffield’s National Health Service community menopause individually prescribed according to the principle of ‘like clinic has run a

Microsoft word - paper k2 target therapies pah policy.doc

National Specialised Commissioning Group Commissioning Policy Target therapies for the treatment of pulmonary arterial hypertension in C:\Documents and Settings\goldingg\Local Settings\Temporary Internet Files\OLKC7\Paper K2 Target Therapies PAH COMMISSSIONING POLICY – TARGET THERAPIES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN ADULTS BACKGROUND In Apri

Copyright © 2010-2014 Medical Articles